AMERSHAM, United Kingdom,
July 27, 2021 /CNW/ -- An ongoing
strategic growth plan from Cytiva and Pall Corporation, part of the
Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity
and services across geographies for global life sciences
The investment, already underway, includes new sites, expansion
at existing factories, and is additional to previously announced
investments. It follows five acquisitions made by the
companies so far this year.
Emmanuel Ligner, Danaher Group
Executive, says: "Our customers tell us they need access to
manufacturing agility, a robust global supply chain and more
regional options. This investment further fuels our expansion
program so we can rapidly meet the current and future needs of our
customers and ultimately, their patients."
Cytiva and Pall Corporation's capacity expansion will increase
the manufacture of key products used to make biologic
The companies are investing:
- 600+ million USD in chromatography resins – media for
analyzing or purifying biomolecules – establishing a new
manufacturing site in the US.
- 400+ million USD in cell culture media – in liquid or
powder form this is used to grow and cultivate cells before they
are purified– expand operations in the US, UK, and Austria.
- 300+ million USD in single-use technologies – including
bioreactor bags for growing cells used to make personalized
medicines and syringe filters for scientific research – expand
operations in the US and the UK, as well as fitting out a new
facility in Cardiff, Wales.
- 200+ million USD for continuing expansion work in Cytiva
and Pall Corporation's sites across China and the rest of the Asia-Pacific region, Europe, and the US.
This investment also addresses some of the key challenges
highlighted in the Global Biopharma Resilience Index, conducted by
Longitude, a Financial Times company, and published by Cytiva in
March 2021. These include hiring and
training talent, R&D collaboration, supply chain resilience,
manufacturing models, as well as government policy and
Pall Corporation is a filtration,
separation and purification leader providing solutions to meet the
critical fluid management needs of customers across the broad
spectrum of life sciences and industry. Part of the Danaher
(NYSE: DHR) family of science and technology
innovators, Pall works with customers to advance
health, safety and environmentally responsible technologies. The
Company's engineered products enable process and product innovation
and minimize emissions and waste. Pall Corporation serves customers
worldwide. For more information visit
Cytiva is a global life
sciences leader with more than 8,000 associates across 40 countries
dedicated to advancing and accelerating therapeutics. Part
of the Danaher (NYSE: DHR) family of science and technology
innovators, Cytiva is a
trusted partner to customers that range in scale and
scope, Cytiva brings speed, efficiency and capacity to research and
manufacturing workflows, enabling the development, manufacture and
delivery of transformative medicines to patients. For more
information visit www.cytiva.com.